31.05.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC FORMS ACADEMIC BRIDGE 'LAB591' WITH ARIX BIOSCIENCE AND FRED HUTCHINSON CANCER RESEARCH CENTER
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC FORMS ACADEMIC BRIDGE 'LAB591' WITH ARIX BIOSCIENCE AND FRED
HUTCHINSON CANCER RESEARCH CENTER
31.05.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* COMBINATION OF ONE OF THE PREMIER CANCER RESEARCH CENTRES WITH A STRONG
COMPANY BUILDER AND EVOTEC'S DRUG DISCOVERY EXPERTISE TO CREATE AND
SUPPORT NEW COMPANIES FOCUSED ON THERAPEUTIC BREAKTHROUGHS FOR PATIENTS
IN THE AREAS OF ONCOLOGY AND INFECTIOUS DISEASES
* EXPANDS EVOTEC'S ACADEMIC 'BRIDGE' INITIATIVE UNDER EVT INNOVATE
* INITIAL TERM OF LAB591 IS FIVE YEARS
Hamburg, Germany, 31 May 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today the formation of the LAB591 academic BRIDGE with Arix
Bioscience plc ("Arix", London Stock Exchange: ARIX ) the Fred Hutchinson
Cancer Research Center ("Fred Hutch").
LAB591 aims to accelerate research discoveries at Fred Hutch and leverage
these discoveries to form new companies focused on cancer and infectious
disease drug development. Evotec, Arix and Fred Hutch plan to jointly select
promising LAB591 research projects from the Fred Hutch labs. After
developing a research validation plan, Evotec will conduct research in
collaboration with the Fred Hutch faculty which will be seed funded by Arix.
Once completed, and subject to the results, Evotec and Arix have a
pre-agreed option to form a new company. For Evotec, the formation of LAB591
represents execution on the BRIDGE model under EVT Innovate, which is met
with a high level of interest by academics, investors and biopharma
companies.
Jonathan Peacock, Chairman of Arix, said: "We are excited to be combining
forces with one of the world's premier cancer research centres and
amplifying this with Evotec's drug discovery engine. This new strategic
collaboration provides us with an excellent platform to identify new
opportunities and build companies with validated, novel scientific
approaches, focused on therapeutic breakthroughs for patients suffering from
cancer and infectious diseases."
Dr Werner Lanthaler, Chief Executive Officer of Evotec, remarked: "We are
excited to work with Fred Hutch, a partner with top-class science and
significant experience in cancer and infectious disease research, and
together with Arix's extensive experience we aim to identify new
opportunities and build companies to discover much needed cures. This BRIDGE
demonstrates Evotec's strong and long-lasting commitment to collaboration
and innovation and we are convinced that we are meeting the needs of
universities and commercial partners and are filling a crucial gap with this
model."
Hilary Hehman, Fred Hutch director of partnerships and alliances, added:
"This partnership is an example of Fred Hutch's commitment to establishing
high-impact strategic partnerships that accelerate the translation of Fred
Hutch's scientific innovation into treatments that ultimately benefit
patients. We believe this partnership will advance our mission to cure
cancer, and we look forward to working closely with Evotec and Arix over the
next five years."
The name of the BRIDGE "LAB591" is in honourable memory of the brother of Dr
William Hutchinson who founded Fred Hutch. His brother, Fred Hutchinson,
died of cancer at an early age in the midst of his professional baseball
career. Fred was a major-league pitcher who threw 591 strikeouts during the
course of his career and the partners chose "LAB591" as a tribute to his
legacy.
ABOUT ARIX BIOSCIENCE PLC
Arix Bioscience plc is a global healthcare and life science company
supporting medical innovation. Headquartered in London and with an office in
New York, Arix Bioscience sources, finances and builds world-class
healthcare and life science businesses addressing medical innovation at all
stages of development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with leading
research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock
Exchange.
ABOUT FRED HUTCHINSON CANCER RESEARCH CENTER
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates,
interdisciplinary teams of world-renowned scientists seek new and innovative
ways to prevent, diagnose and treat cancer, HIV/AIDS and other
life-threatening diseases. Fred Hutch's pioneering work in bone marrow
transplantation led to the development of immunotherapy, which harnesses the
power of the immune system to treat cancer. An independent, nonprofit
research institute based in Seattle, Fred Hutch houses the nation's first
National Cancer Institute-funded cancer prevention research program, as well
as the clinical coordinating center of the Women's Health Initiative and the
international headquarters of the HIV Vaccine Trials Network.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. with Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
31.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
691199 31.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT